The Rise of the Machines: ECMO for the General Intensivist

A Comprehensive Review of Patient Selection, Circuit Management, and Ethical Considerations

Dr Neeraj Manikath , claude.ai

Abstract

Extracorporeal membrane oxygenation (ECMO) has evolved from a specialized cardiothoracic procedure to an essential tool in modern critical care medicine. As ECMO programs expand globally, general intensivists must develop competency in patient selection, circuit management, and ethical decision-making. This review provides practical guidance for the general intensivist, emphasizing patient selection criteria over technical cannulation details, circuit troubleshooting strategies, and the complex ethical landscape of ECMO therapy. We present evidence-based recommendations, clinical pearls, and management "hacks" derived from contemporary literature and expert consensus to enhance clinical decision-making in ECMO care.

Keywords: ECMO, extracorporeal membrane oxygenation, critical care, patient selection, ethics, intensivist

Introduction

The landscape of critical care has been revolutionized by the increasing availability of extracorporeal membrane oxygenation (ECMO). Once confined to specialized cardiac surgery centers, ECMO has become an integral component of modern intensive care medicine. The COVID-19 pandemic accelerated this transformation, with many institutions rapidly expanding their ECMO capabilities to manage severe ARDS cases¹.

For the general intensivist, ECMO represents both an opportunity and a challenge. The technology offers life-saving potential for patients with reversible cardiopulmonary failure, yet demands sophisticated clinical judgment, resource allocation, and ethical consideration. This review aims to equip the general intensivist with practical knowledge focusing on three critical domains: patient selection, circuit management, and ethical decision-making.

Historical Context and Current Landscape

ECMO technology has evolved significantly since Robert Bartlett's pioneering work in the 1970s². The Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial in 2009 demonstrated improved survival when ECMO was used in experienced centers³. Subsequently, the H1N1 influenza pandemic and more recently COVID-19 have expanded ECMO utilization worldwide⁴.

Pearl: The success of ECMO depends more on center experience and patient selection than on the technology itself. Volume matters – centers performing >20 cases annually demonstrate superior outcomes⁵.

Patient Selection: The Art of Saying Yes (and No)

VV-ECMO for ARDS: The Good Candidates

Patient selection represents the most critical decision in ECMO care. For venovenous (VV) ECMO in ARDS, the ideal candidate possesses several characteristics:

Primary Criteria:

Age <65 years (relative contraindication >70 years)
Reversible pulmonary pathology
Murray score >2.5 or pH <7.20 despite optimal ventilation
P/F ratio <80 on FiO₂ >0.8 for >6 hours
Plateau pressures >30 cmH₂O despite lung-protective ventilation⁶

Clinical Pearl: The "RESP Score" (Respiratory ECMO Survival Prediction) provides validated risk stratification. Scores >3 predict good outcomes, while scores <-2 suggest poor prognosis⁷.

RESP Score Components:

Age (18-49: +3, 50-59: +2, 60+: 0)
Immunocompromised status (-2)
Mechanical ventilation duration (<7 days: +1, >14 days: -1)
Diagnosis (viral pneumonia: +3, bacterial: +2, trauma: +2, aspiration: +1)
CNS dysfunction (-7)
Acute renal failure (-3)
Cardiac arrest (-2)
Peak inspiratory pressure (<42 cmH₂O: +1)

The Red Flags: When to Say No

Absolute contraindications remain limited, but several factors predict futility:

Absolute Contraindications:

Irreversible multiorgan failure
Intracranial hemorrhage
Metastatic malignancy with poor prognosis
Advanced directive precluding life support

Relative Contraindications:

Mechanical ventilation >14 days
Major bleeding or coagulopathy
Severe peripheral vascular disease
Morbid obesity (BMI >40)
Advanced age with comorbidities⁸

Oyster Alert: Immunocompromised patients were historically excluded, but recent data suggests selected patients (especially those with reversible causes) may benefit. The key is identifying truly reversible pathology⁹.

VA-ECMO Considerations

Venoarterial (VA) ECMO for cardiogenic shock requires different selection criteria:

Ideal VA-ECMO Candidate:

Age <70 years
Reversible cardiac pathology
No significant multiorgan failure
Suitable for bridge to recovery, transplant, or device
Lactate <10 mmol/L¹⁰

Clinical Hack: Use the "SAVE Score" (Survival After Veno-Arterial ECMO) for prognostication. Scores >5 predict good outcomes¹¹.

Circuit Management: The Nuts and Bolts

Troubleshooting Hypoxia on VV-ECMO

Persistent hypoxia despite ECMO represents a common challenge with multiple potential causes:

Systematic Approach to Hypoxia:

Circuit Issues (Check First):
- Recirculation (drainage cannula position)
- Circuit flow rates (<3.5 L/min often inadequate)
- Oxygenator failure (check post-oxygenator saturation)
- Air emboli
Patient Factors:
- Intracardiac shunting (PFO, VSD)
- Pulmonary embolism
- Pneumothorax
- Native lung contribution (<10%)
Technical Solutions:
- Increase sweep gas flow (affects CO₂ removal)
- Increase blood flow (affects O₂ delivery)
- Consider dual-site cannulation
- Optimize cannula position with echocardiography¹²

Management Hack: The "80-80-80 Rule" for VV-ECMO adequacy:

Circuit flow >80% of cardiac output
Pre-oxygenator saturation >80%
Post-oxygenator saturation >80%

Anticoagulation Strategies

Anticoagulation remains one of the most challenging aspects of ECMO management:

Standard Approach:

Unfractionated heparin (UFH) remains gold standard
Target aPTT 60-80 seconds (1.5-2.5x normal)
Alternative: Anti-Xa levels 0.3-0.7 IU/mL
Monitor with ACT, aPTT, and anti-Xa¹³

Special Situations:

Bleeding Complications:

Hold anticoagulation temporarily
Consider aminocaproic acid or tranexamic acid
Reduce circuit flow if necessary
Circuit change may be required¹⁴

Heparin Resistance:

Antithrombin III deficiency (supplement to >80%)
Consider direct thrombin inhibitors (bivalirudin)
Argatroban as alternative¹⁵

Clinical Pearl: Daily monitoring should include CBC, PT/aPTT/INR, fibrinogen, D-dimer, and LDH. Rising LDH suggests hemolysis and potential circuit thrombosis.

Team Management and Communication

ECMO requires multidisciplinary coordination:

Core Team Members:

Intensivist (medical management)
ECMO specialist (circuit management)
Perfusionist (technical expertise)
ECMO nurse (bedside care)
Respiratory therapist (ventilator management)

Communication Strategies:

Daily multidisciplinary rounds
Standardized handoff protocols
Clear escalation pathways
Family communication lead designation¹⁶

Ventilator Management During ECMO

VV-ECMO allows ultra-lung-protective ventilation, but optimization requires careful titration:

Initial Settings:

FiO₂ 0.3-0.4
PEEP 10-15 cmH₂O
Tidal volume 3-4 mL/kg IBW
Respiratory rate 10-20/min
Plateau pressure <25 cmH₂O¹⁷

Weaning Strategy:

Maintain recruitment with adequate PEEP
Gradually increase FiO₂ and tidal volumes
Monitor compliance and gas exchange
Daily spontaneous breathing trials when appropriate

Oyster: Avoid complete ventilator rest – maintain some ventilation to prevent atelectasis and promote lung healing¹⁸.

Complications and Troubleshooting

Circuit-Related Complications

Oxygenator Failure:

Gradual increase in pre-post pressure differential
Declining gas exchange efficiency
Rising plasma-free hemoglobin
Management: Circuit change required¹⁹

Pump Thrombosis:

Sudden increase in pump pressures
Visible clot formation
Hemolysis markers
Management: Emergency circuit change

Air Embolism:

Sudden neurological deterioration
Circuit air detection alarms
Management: Immediate Trendelenburg position, 100% O₂, consider hyperbaric therapy²⁰

Patient-Related Complications

Bleeding: Most common complication (30-50% incidence)

GI bleeding most frequent
Intracranial hemorrhage most feared
Management requires anticoagulation balance²¹

Infection:

Bloodstream infections common
Circuit colonization
Pneumonia in native lungs
Antimicrobial stewardship essential²²

Renal Failure:

Acute kidney injury in 70% of patients
Continuous renal replacement therapy often required
Integrated ECMO-CRRT circuits available²³

The Ethics of ECMO: Navigating Complex Decisions

When to Say No: Futility Considerations

ECMO's life-sustaining capability creates ethical challenges. Clear criteria help navigate these decisions:

Futility Indicators:

Irreversible multiorgan failure
Malignancy with <6-month life expectancy
Severe neurological injury
Patient/family preference against aggressive care²⁴

Clinical Hack: The "5-Day Rule" – if no improvement in organ function within 5 days of optimal ECMO support, reassess goals of care²⁵.

Shared Decision-Making Framework

ECMO decisions require structured communication:

Key Discussion Points:

Prognosis with and without ECMO
Quality of life considerations
Resource utilization implications
Alternative treatment options
Time-limited trial concept²⁶

Communication Strategy:

Early involvement of ethics consultation
Regular family meetings
Clear documentation of goals
Consideration of cultural factors

Resource Allocation

ECMO programs must address resource scarcity:

Allocation Principles:

Medical appropriateness
Likelihood of benefit
First-come, first-served (when medically equivalent)
Fair process implementation²⁷

Institutional Requirements:

Ethics committee involvement
Clear allocation protocols
Appeals process
Staff support systems

Quality Improvement and Outcomes

Key Performance Indicators

Successful ECMO programs monitor standardized metrics:

Process Measures:

Time to cannulation
Appropriate patient selection
Complication rates
Length of stay²⁸

Outcome Measures:

Survival to discharge
Neurological outcomes
Quality of life scores
Resource utilization

Registry Participation

International ECMO Organization (ELSO) Registry:

Mandatory for quality programs
Benchmark comparisons
Risk adjustment models
Best practice dissemination²⁹

Clinical Pearl: Centers should aim for >70% survival in VV-ECMO for viral pneumonia and >50% for VA-ECMO in cardiogenic shock³⁰.

Future Directions and Innovations

Technological Advances

Miniaturization:

Smaller, more mobile circuits
Ambulatory ECMO systems
Reduced priming volumes³¹

Biocompatible Surfaces:

Heparin-bonded circuits
Reduced anticoagulation requirements
Lower bleeding risks³²

Artificial Intelligence:

Predictive algorithms
Automated flow adjustments
Early complication detection³³

Expanding Indications

Bridge to Lung Transplant:

Awake ECMO protocols
Rehabilitation during support
Improved transplant outcomes³⁴

Cardiac Arrest:

ECPR (extracorporeal CPR)
Selected in-hospital arrests
Rapid response teams³⁵

Practical Implementation Guide

Program Development

Essential Components:

Medical director with ECMO expertise
24/7 availability
Standardized protocols
Continuous education program
Quality assurance process³⁶

Staffing Model:

ECMO specialists (physicians/nurses)
Perfusion support
Respiratory therapy
Surgical backup

Training Requirements

Core Competencies:

Patient selection criteria
Circuit management
Complication recognition
Ethical decision-making
Family communication³⁷

Simulation-Based Training:

Emergency scenarios
Circuit complications
Team communication
Decision-making skills

Clinical Decision-Making Algorithms

VV-ECMO Initiation Algorithm

Assess Candidacy
- Age, comorbidities, prognosis
- Calculate RESP score
- Evaluate reversibility
Optimize Conventional Therapy
- Lung-protective ventilation
- Prone positioning
- Neuromuscular blockade
- Recruitment maneuvers
ECMO Consideration Triggers
- P/F ratio <80 for >6 hours
- pH <7.20 despite optimization
- Plateau pressures >30 cmH₂O
Team Discussion
- Multidisciplinary consensus
- Family meeting
- Goals of care clarification
Cannulation Decision
- Ensure appropriate expertise
- Prepare for complications
- Establish monitoring protocols³⁸

Conclusion

ECMO has transitioned from an experimental therapy to a standard component of critical care practice. For the general intensivist, success depends not on technical cannulation skills, but on masterful patient selection, meticulous circuit management, and thoughtful ethical decision-making.

The key principles for the general intensivist include: prioritizing patient selection over technical complexity, understanding that ECMO is a bridge therapy requiring exit strategy, recognizing that complications are common and potentially catastrophic, and maintaining clear communication with patients, families, and teams.

As ECMO technology continues to evolve, the general intensivist must balance innovation with evidence, hope with reality, and resource allocation with individual patient needs. The "rise of the machines" in critical care represents both tremendous opportunity and significant responsibility.

Final Pearl: ECMO doesn't cure disease – it buys time. Use that time wisely.

References

Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020;396(10257):1071-1078.
Bartlett RH, Gazzaniga AB, Jefferies MR, et al. Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy. Trans Am Soc Artif Intern Organs. 1976;22:80-93.
Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351-1363.
Davies A, Jones D, Bailey M, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302(17):1888-1895.
Barbaro RP, Odetola FO, Kidwell KM, et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Am J Respir Crit Care Med. 2015;191(8):894-901.
Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965-1975.
Schmidt M, Bailey M, Sheldrake J, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. Am J Respir Crit Care Med. 2014;189(11):1374-1382.
Munshi L, Walkey A, Goligher E, et al. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med. 2019;7(2):163-172.
Wohlfarth P, Ullrich R, Staudinger T, et al. Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. Crit Care. 2014;18(1):R20.
Thiagarajan RR, Barbaro RP, Rycus PT, et al. Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J. 2017;63(1):60-67.
Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J. 2015;36(33):2246-2256.
Koerner MM, Harper MD, Gibbs KW, et al. Blood flow during cardiopulmonary resuscitation with simultaneous intraaortic balloon pumping in a canine model of acute myocardial dysfunction. Circulation. 1999;99(10):1341-1349.
McMichael ABV, Ryerson LM, Ratano D, et al. 2021 ELSO Adult and Pediatric Anticoagulation Guidelines. ASAIO J. 2022;68(3):303-310.
Kasirajan V, Smedira NG, McCarthy JF, et al. Risk factors for intracranial hemorrhage in adults on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg. 1999;15(4):508-514.
Young G, Yonekawa KE, Nakagawa P, et al. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion. 2004;19(5):283-288.
Extracorporeal Life Support Organization. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. Version 1.4. Ann Arbor, MI: ELSO; 2017.
Schmidt M, Pham T, Arcadipane A, et al. Mechanical ventilation management during extracorporeal membrane oxygenation for acute respiratory distress syndrome. Crit Care Med. 2019;47(9):1244-1251.
Marhong JD, Telesnicki T, Munshi L, et al. Mechanical ventilation during extracorporeal membrane oxygenation. An international survey. Ann Am Thorac Soc. 2014;11(6):956-961.
Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8(5):518-526.
Hsu PS, Chen JL, Hong GJ, et al. Extracorporeal membrane oxygenation for refractory cardiogenic shock after adult cardiac surgery. Ann Thorac Surg. 2010;90(1):63-68.
Cheng R, Hachamovitch R, Kittleson M, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014;97(2):610-616.
Bizzarro MJ, Conrad SA, Kaufman DA, et al. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. 2011;12(3):277-281.
Fleming GM, Sahay R, Zappitelli M, et al. The incidence of acute kidney injury and its effect on neonatal and pediatric extracorporeal membrane oxygenation outcomes: a multicenter report from the kidney intervention during extracorporeal membrane oxygenation study group. Pediatr Crit Care Med. 2016;17(12):1157-1169.
Sulmasy DP, Bledsoe TA, Kathryn L, et al. The ethical implications of extracorporeal membrane oxygenation in adults with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2018;198(6):720-727.
Wilcox ME, Adhikari NK, Anthony C, et al. The effect of extracorporeal membrane oxygenation on end-of-life care in the ICU. Chest. 2015;148(1):215-221.
Curtis JR, Kross EK, Stapleton RD. The importance of addressing advance care planning and decisions about do-not-resuscitate orders during novel coronavirus 2019 (COVID-19). JAMA. 2020;323(18):1771-1772.
Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical interventions. Lancet. 2009;373(9661):423-431.
Tonna JE, Abrams D, Brodie D, et al. Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the Extracorporeal Life Support Organization (ELSO). ASAIO J. 2021;67(6):601-610.
Thiagarajan RR, Barbaro RP, Rycus PT, et al. Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J. 2017;63(1):60-67.
Karagiannidis C, Brodie D, Strassmann S, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med. 2016;42(5):889-896.
Madhani SP, Frankowski BJ, Burgreen GW, et al. In vitro and in vivo evaluation of a novel integrated wearable artificial lung. J Heart Lung Transplant. 2017;36(7):806-811.
Martucci G, Grasselli G, Tanaka K, et al. New-generation extracorporeal membrane oxygenators with polymethylpentene oxygenators are associated with reduced thrombotic events in comparison with silicone oxygenators. Interact Cardiovasc Thorac Surg. 2021;32(5):643-649.
Jalali A, Bender SP, Rehder KJ, et al. Extracorporeal membrane oxygenation weaning prediction using artificial neural network. ASAIO J. 2019;65(5):493-499.
Hoetzenecker K, Schwarz S, Muckenhuber M, et al. Intraoperative extracorporeal membrane oxygenation and the possibility of postoperative prolongation improve survival in bilateral lung transplantation. J Thorac Cardiovasc Surg. 2018;155(5):2193-2206.
Richardson ASC, Tonna JE, Nanjayya V, et al. Extracorporeal cardiopulmonary resuscitation in adults. Interim guideline consensus statement from the extracorporeal life support organization. ASAIO J. 2021;67(3):221-228.
MacLaren G, Combes A, Bartlett RH. Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med. 2012;38(2):210-220.
Makdisi G, Wang IW. Extra corporeal membrane oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015;7(7):E166-E176.
Extracorporeal Life Support Organization. General Guidelines for all ECLS Cases. Version 1.4. Ann Arbor, MI: ELSO; 2017.

Tuesday, August 19, 2025